“Precision data, surgical restraint & breakthrough immunotherapy are transforming lung cancer care.” In the STS Best of Lung Cancer Science resource, Dr. Erin Gillaspie & Dr. Leah Backhus offer key insights from #WCLC2025. Listen to the podcast & read the executive summary. https://ow.ly/B3ZH50XGXrG

STAS is Associated with Poor Prognosis in Early-Stage NSCLC Regardless of Surgical Approach - ILCN.org (ILCN/WCLC) JCOG0802/WJOG4607L data validate segmentectomy as non-inferior to lobectomy, regardless of the presence of STAS, Dr. Yasushi Yatabe said.

#WCLC2025 recap: STAS is associated with poor prognosis in early-stage NSCLC, regardless of surgical approach.
Read the latest data from Dr. Yasushi Yatabe in ILCN: bit.ly/4nl8ijw

#LCSM

Lost in Translation: Survey Reveals Critical Communication Gaps in Lung Cancer Care - ILCN.org (ILCN/WCLC) Complex information and poor communication were identified as major obstacles to meaningful participation in decision-making, according to data presented by patient advocate Debra Montague.

At #WCLC2025, patient advocate Debra Montague unveiled new survey data showing serious communication challenges in lung cancer care.
Full story in ILCN: https://bit.ly/48MyLD8
#LCSM

🚨 Exciting milestone! TRACKER PhD Candidate Dr Senthuran Shivakumar presented his first 2 posters at #WCLC2025 🎉 His research discovers biomarkers of checkpoint inhibitor pneumonitis to enable sustainable, high-quality survivorship.

New Lung Cancer Considered from WCLC 2025 - IASLC - OncoDaily New Lung Cancer Considered from WCLC 2025 - IASLC / cancer, IASLC, Narjust Florez, OncoDaily, Oncology, Stephen V Liu, WCLC 2025, WCLC2025

IASLC - New Lung Cancer Considered from WCLC 2025

@iaslc.bsky.social @stephenvliu.bsky.social @narjustflorezmd.bsky.social

oncodaily.com/voices/lung-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WCLC2025 #IASLC #LungCancer

In metastatic EGFR-mutated non-small cell #LungCancer (#NSCLC), targeting residual disease through surgery can extend the benefits of #EGFR TKI therapy beyond standard monotherapy, a new study presented at the @iaslc.bsky.social‬ #WCLC2025 finds.

How does new evidence guide decisions in lung cancer care? Get the expert updates you need to know from #WCLC2025 on imaging tools, from emerging technologies to their evolving role in lung cancer staging, with our swipe through symposia summaries 🫁 #MedSky #CancerSky

ow.ly/ggtm50WXBjC

To Screen, or Not to Screen? It’s A Question of Age Older people found to have lung cancer through screening are more likely to die from any cause than their younger counterparts, but are just as likely to survive the disease following surgery.

Is it time to rethink lung cancer screening age limits?
New research shows older adults can benefit—if they’re fit enough for surgery.
@neilosterweil.bsky.social's latest for Medical News Insider from #WCLC2025: medicalnewsinsider.substack.com/p/to-screen-...
#PublicHealth #CancerCare

LCC in Mandarin: WCLC 2025 Highlights | IASLC The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer resear ...

What were the biggest research stories at #WCLC2025?
In this Mandarin episode of Lung Cancer Considered, Dr. Chunxia Su speaks with Dr. Yang Xia and Dr. Nan Bi about the most impactful findings from this year’s conference.

🎧 Listen here: bit.ly/3Il284D

#IASLC #LungCancer #WCLC2025 #Oncology

WCLC 2025: IFITM3 May Improve Immunotherapy Outcomes in SCLC New research identifies IFITM3 as a driver of immunotherapy response in small cell lung cancer, improving MHC-I expression and CD8⁺ T cell activity, with potential as biomarker and target.

🌍 At #WCLC2025, researchers revealed IFITM3 as a key driver of immunotherapy response in SCLC, boosting antigen presentation and T cell activity while emerging as a potential biomarker and target.

www.emjreviews.com/en-us/amj/re...

#AMJRespiratory #LungCancer #Immunotherapy #WCLC

CT Lung Screening, CT Radiation Effects, and GE to Buy icometrix - The Imaging Wire CT lung screening news from WCLC 2025, CT radiation before conception, GE to buy icometrix, MRI predicts aneurysm rupture, and much more.

Issue #737 of The Imaging Wire is live:

- CT Lung Cancer Screening News from #WCLC2025
- CT Radiation Before Conception
- Faster MRI for Prostate Cancer
- MRI Predicts Aneurysm Rupture Risk

Read more at theimagingwire.com/newsletter/c....

#radiology #lungcancer

'Unprecedented' Survival Seen With Maintenance Tarlatamab for SCLC in Early Study 'I know I'm supposed to be critical, but it's a wow,' one expert says

The combination of tarlatamab (Imdelltra) and a PD-L1 inhibitor after first-line chemo-immunotherapy showed promise as a maintenance therapy in patients with ES-SCLC, with a manageable safety profile, according to the phase Ib DeLLphi-303 trial. #WCLC2025
www.medpagetoday.com/meetingcover...

#ONCOnews #OncoAlert #OncEd #WCLC2025 #LungCancer #NSCLC

At #WCLC2025, the NAUTIKA1 study showed the impact of giving alectinib before surgery in early-stage ALK+ #lungcancer:

60.7% major pathological response, 25% complete response, 63% radiographic responses after just 8 weeks.

Surgery still needed - and it all starts with biomarker testing! #LCSM

If you liked our coverage of #WCLC25, why not visit our expert resources for more of the latest updates in oncology? From podcasts to congress highlights, get closer to the conversations that matter with Medthority

#Oncology #MedX #WCLC2025

ow.ly/hgL450WTLcy

That's it for our LIVE coverage of 'Challenging Scenarios for Immunotherapy Treatment' at #WCLC25 🫁 Chaired by
Thanyanan Baisamut & Tom John, speakers tackled tough cases from autoimmune disease to brain metastases & ICI rechallenge

#Oncology #MedX #IASLC #LungCancer #WCLC2025

Expert insights from Satoru Miura at #WCLC25

🔹 In ICI rechallenge, irAEs recur in 18–44% of cases
🔹 #ASCO & #ESMO guidelines stress case-by-case multidisciplinary decisions
🔹 Type & severity of initial irAE aids decision

#Oncology #MedSky #IASLC #LungCancer #WCLC2025

Thomas John on immunotherapy in brain metastases at #WCLC25

🔹 CNS TME differs from extracranial sites
🔹 Most brain metastases generate immunosuppressive environments
🔹 Data shows combo immunotherapy responses are good but lack durability

#Oncology #MedSky #IASLC #LungCancer #WCLC2025

The cancer "silver tsunami" is coming! More from Roberto Ferrara on treating elderly patients with immunotherapy at #WCLC25

🔹 Performance status definition is too subjective and heterogeneous

#Oncology #MedSky #IASLC #LungCancer #WCLC2025

Latest on treating elderly frail patients with immunotherapy from Roberto Ferrara at #WCLC25

🔹 Elderly patients not included in pivotal trials
🔹 Biological age & immunosenescence may guide decisions better than chronological age

#Oncology #MedSky #IASLC #LungCancer #WCLC2025

Navigating immunotherapy in complex cases?
@nymurakami.bsky.social shares her insights at #WCLC25

🔹 AEs vary in tempo & severity
🔹 ICIs show efficacy but trial data lacking for these groups
🔹 Multidisciplinary monitoring is key

#Oncology #MedSky #IASLC #LungCancer #WCLC2025

1 hour to go! Stay tuned for expert insights from today’s 'Challenging Scenarios for Immunotherapy Treatment' symposium at #WCLC25. Follow along here for the live updates you need to know

#MedSky #LungCancer #WCLC2025 #IASLC

At #WCLC2025, Henlius shared data on HLX43, an anti-PD-L1 ADC, in advanced NSCLC. It showed a 37% ORR, 87% DCR, and 5.4-month mPFS across subgroups, including brain mets. Safety was manageable; irAEs linked to better outcomes. Results support further trials, including frontline use.

🔵🫁 @aeacap.bsky.social ha asistido a la #WCLC2025 para conocer los últimos avances científicos y clínicos vinculados a la prevención, el diagnóstico y el tratamiento del #cáncerdepulmón

➡️ También se han expuesto los avances en terapias dirigidas y enfoques multidisciplinares

#MedSky: Couldn’t make it to the World Conference on Lung Cancer?

Here’s what you need to know from #WCLC2025. ⬇️ (and stay tuned for updates! ✨)

That’s a wrap on 'Imaging Tools for Staging: New Kids on the Block ' at #WCLC25! From smoking status to controversies, PET/CT & EBUS, experts shared staging insights & clinical impact.

Enjoyed our coverage? Explore oncology resources over on Medthority ow.ly/Qi8M50WTbJS

#MedSky #WCLC2025 #IASLC

Daniel Steinfort joins via video at #WCLC25

Why perform systematic staging in lung cancer?
Steinfort shows clinic images to highlight how imaging guides referrals, plus discusses a meta-analysis of 25 studies on systematic clinical staging

#Oncology #IASLC #LungCancer #WCLC2025 #MedSky

Jeremy Erasmus on issues using PET/CT in lung cancer staging at #WCLC25

🔹 PET/CT improves overall & nodal staging
🔹 Sensitivity & specificity better—but still not optimal for nodal staging
🔹Should be used in most surgical candidates

#Oncology #IASLC #LungCancer #WCLC2025 #MedSky

Kyongmin Sarah Beck considers imaging controversies in lung cancer staging at #WCLC25

🔹 Lymphangitic carcinomatosis not addressed in TNM staging
🔹 NSCLC study: cLy1/2 without distant or mediastinal metastases should be surgical candidates

#Oncology #IASLC #LungCancer #WCLC2025 #MedSky